BRANFORD, Conn., Nov. 1 /PRNewswire-FirstCall/ -- Neurogen Corporation , a drug discovery and development company, announced today that it will release its third quarter of 2005 financial results on Tuesday, November 8, 2005 before the opening of the U.S. financial markets. The Company will host a conference call and live audio webcast that same day at 10:00 ET to review the results.
The news release and live webcast may be accessed through the investor relations section of the Company’s web site: http://www.neurogen.com. The webcast will be also be archived in this section, under “Events Calendar and Replays.”
The webcast is also being distributed through the Thomson StreetEvents Network to both institutional and individual investors. Individual investors can listen to the call at www.fulldisclosure.com, Thomson/CCBN’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson’s password-protected event management site, StreetEvents (www.streetevents.com).
About Neurogen
Neurogen Corporation targets new small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including pain, insomnia, depression, inflammation, and obesity. Neurogen has generated a portfolio of compelling new drug candidates through its Accelerated Intelligent Drug Discovery (AIDD(TM)) system, its expertise in cellular functional assays, and its depth in medicinal chemistry. Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to obtain additional resources and to access complementary expertise.
Neurogen Corporation
CONTACT: Elaine Grimsell Dodge, Associate Director Investor & PublicRelations of Neurogen Corporation, +1-203-315-4615, or edodge@nrgn.com
